News | July 23, 2012

First Patient Enrolled in the EuroEco ICD/CRT-D Trial Assessing Economic Effect of Home Monitoring

July 23, 2012 — Biotronik announced that the first CRT-D patient has been enrolled in the Biotronik EuroEco Trial — the European Health Economic Trial on Home Monitoring in implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy device (CRT-D) patients. The aim of the study is to assess the economic effects of Biotronik Home Monitoring-based remote follow-up management compared to conventional in-clinic or practice follow-ups.

In the study, the economic impact on the hospital — expressed as total follow-up cost — will be assessed and the cost effectiveness will be evaluated as a secondary analysis. The trial has been extended to incorporate CRT-D patients after more than 300 ICD patients enrolled in the first stage of the trial.

Biotronik Home Monitoring is a system that provides continuous, automatic, wireless remote monitoring of patient status and device status with daily updates — all independent of any patient interaction. The landmark trial TRUST and the COMPAS study have proven that Biotronik Home Monitoring leads to early detection of clinically relevant events and therefore to an earlier intervention and reduction of hospitalizations.

“Studies on the economic effects of remote follow-ups are still sparse,” said Dr. Hein Heidbüchel of University Hospital Leuven in Belgium, and coordinating clinical investigator of the trial. “Nevertheless, the financial implications of remote care will drive its acceptance. Authorities and hospitals will need information on how this innovative care can be adequately reimbursed. EuroEco is the first trial where an economic evaluation of remote monitoring is the primary endpoint.”

The EuroEco trial is a randomized, multicenter, international clinical trial with 312 ICD patients, and in its extension 104 CRT-D patients — a total of 416 patients in 15 European sites — with each patient having a 24-month follow-up.

“The Biotronik Home Monitoring remote follow-ups are able to enhance the safety and quality of patients’ lives by allowing for earlier detection of clinically relevant events and avoiding hospitalizations,” said Christoph Böhmer, president international at Biotronik. “We can proceed from the assumption that the systematic and continuous remote monitoring with Biotronik Home Monitoring will have clear effects on cost effectiveness and savings for the healthcare system.”

For more information: www.biotronik.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
Overlay Init